Doxycycline Hyclate side effects: what 67,065 FDA adverse event reports show
Drug class
Not stated in label
Who reports
67,065 reports · 73% serious · 6,708 with death outcome · 63% female
Used for
To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
What it is
DESCRIPTION Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as doxycycline hyclate tablets for oral administration. The chemical designation o.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,165 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Amyloid arthropathy | 55 | 1,878.3 928.4–3,800.4ROR 1,879.9 · calibrated p 6e-17 ✓ | 242.7 EB05 193.5 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=55 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Grip strength | 142 | 501.7 384.2–655.0ROR 502.7 · calibrated p 1e-13 ✓ | 186.4 EB05 162.1 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious n=142 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Congenital hiatus hernia | 119 | 365.8 280.4–477.1ROR 366.4 · calibrated p 3e-12 ✓ | 163.2 EB05 140.0 · IC025 +6.3 3/3 methods agree | Not in label — unassessed | serious n=119 · ♀ 0% (drug 63%) | not reported in cached trials |
| C-reactive protein | 462 | 327.2 287.1–372.9ROR 329.5 · calibrated p 5e-12 ✓ | 158.0 EB05 146.2 · IC025 +6.9 3/3 methods agree | Lab value / disease marker | serious n=462 · ♀ 100% (drug 63%) · 97% clinician | not reported in cached trials |
| Deep vein thrombosis postoperative | 869 | 250.3 229.0–273.7ROR 253.6 · calibrated p 5e-11 ✓ | 138.0 EB05 130.5 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious n=869 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 295 | 249.1 213.7–290.4ROR 250.2 · calibrated p 7e-11 ✓ | 136.8 EB05 124.2 · IC025 +6.6 3/3 methods agree | Lab value / disease marker | serious n=295 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Jarisch-herxheimer reaction | 312 | 244.0 210.4–283.1ROR 245.1 · calibrated p 8e-11 ✓ | 135.4 EB05 123.2 · IC025 +6.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=297 · ♀ 29% (drug 63%) · 100% clinician | not reported in cached trials |
| Swollen joint count | 106 | 237.8 184.6–306.4ROR 238.2 · calibrated p 2e-10 ✓ | 131.4 EB05 111.7 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=106 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Lupus vulgaris | 509 | 234.9 209.4–263.6ROR 236.7 · calibrated p 1e-10 ✓ | 132.9 EB05 123.5 · IC025 +6.7 3/3 methods agree | Not in label — unassessed | serious n=509 · ♀ 100% (drug 63%) · 96% clinician | not reported in cached trials |
| Gastrointestinal mucosal necrosis | 56 | 200.1 143.0–280.2ROR 200.3 · calibrated p 1e-9 ✓ | 116.9 EB05 93.3 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=56 · ♀ 0% (drug 63%) · 100% clinician | not reported in cached trials |
| Swollen joint count increased | 1,014 | 150.9 140.1–162.6ROR 153.2 · calibrated p 4e-9 ✓ | 101.4 EB05 96.2 · IC025 +6.5 3/3 methods agree | Lab value / disease marker | serious n=1,014 · ♀ 100% (drug 63%) · 96% clinician | not reported in cached trials |
| Abortion incomplete | 553 | 129.7 117.5–143.3ROR 130.8 · calibrated p 1e-8 ✓ | 91.3 EB05 85.0 · IC025 +6.3 3/3 methods agree | Not in label — unassessed | serious n=203 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 510 | 105.9 95.8–117.1ROR 106.7 · calibrated p 7e-8 ✓ | 78.8 EB05 73.2 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious n=508 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| Rheumatic fever | 1,095 | 104.6 97.7–112.0ROR 106.3 · calibrated p 7e-8 ✓ | 78.2 EB05 74.4 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious n=1,095 · ♀ 100% (drug 63%) · 96% clinician | not reported in cached trials |
| Retinitis | 409 | 101.5 90.8–113.4ROR 102.1 · calibrated p 1e-7 ✓ | 76.3 EB05 70.3 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=409 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Facet joint syndrome | 710 | 90.9 83.6–98.8ROR 91.8 · calibrated p 2e-7 ✓ | 70.2 EB05 66.0 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious n=710 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| X-ray abnormal | 373 | 82.5 73.6–92.5ROR 83.0 · calibrated p 5e-7 ✓ | 65.1 EB05 59.7 · IC025 +5.7 3/3 methods agree | Lab value / disease marker | serious n=373 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Rheumatoid factor positive | 1,183 | 80.6 75.6–85.9ROR 82.0 · calibrated p 5e-7 ✓ | 64.0 EB05 61.0 · IC025 +5.9 3/3 methods agree | Lab value / disease marker | serious n=1,183 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| Dislocation of vertebra | 456 | 80.6 72.7–89.3ROR 81.1 · calibrated p 6e-7 ✓ | 63.9 EB05 59.1 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious n=456 · ♀ 100% (drug 63%) · 93% clinician | not reported in cached trials |
| Overlap syndrome | 122 | 67.1 55.2–81.6ROR 67.2 · calibrated p 2e-6 ✓ | 54.8 EB05 47.1 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=122 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 1,219 | 62.2 58.5–66.1ROR 63.3 · calibrated p 3e-6 ✓ | 51.8 EB05 49.4 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 41.0 · ♀ 100% (drug 63%) · 96% clinician | not reported in cached trials |
| C-reactive protein abnormal | 930 | 53.0 49.5–56.8ROR 53.7 · calibrated p 9e-6 ✓ | 45.3 EB05 42.9 · IC025 +5.4 3/3 methods agree | Lab value / disease marker | serious n=928 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| Bone erosion | 510 | 52.5 47.8–57.6ROR 52.9 · calibrated p 1e-5 ✓ | 44.9 EB05 41.7 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=510 · ♀ 100% (drug 63%) · 97% clinician | not reported in cached trials |
| Seronegative arthritis | 160 | 51.9 43.9–61.3ROR 52.0 · calibrated p 1e-5 ✓ | 44.3 EB05 38.8 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=160 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, insomnia type | 893 | 50.3 46.8–53.9ROR 50.9 · calibrated p 1e-5 ✓ | 43.3 EB05 41.0 · IC025 +5.3 3/3 methods agree | Labeled (related wording) related wording | serious n=890 · ♀ 100% (drug 63%) · 97% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody positive | 919 | 46.3 43.2–49.6ROR 47.0 · calibrated p 2e-5 ✓ | 40.4 EB05 38.2 · IC025 +5.2 3/3 methods agree | Lab value / disease marker | serious PRR 32.1 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| Helicobacter infection | 1,281 | 44.8 42.3–47.5ROR 45.7 · calibrated p 2e-5 ✓ | 39.2 EB05 37.5 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious PRR 32.6 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| Porphyria acute | 172 | 44.4 37.8–52.1ROR 44.5 · calibrated p 3e-5 ✓ | 38.8 EB05 34.1 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=172 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Folliculitis | 1,200 | 41.0 38.6–43.5ROR 41.7 · calibrated p 4e-5 ✓ | 36.3 EB05 34.6 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious PRR 33.4 · ♀ 97% (drug 63%) · 95% clinician | not reported in cached trials |
| Chronic kidney disease-mineral and bone disorder | 119 | 38.8 32.1–46.9ROR 38.9 · calibrated p 7e-5 ✓ | 34.4 EB05 29.5 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=119 | not reported in cached trials |
| Muscle injury | 872 | 37.1 34.6–39.8ROR 37.6 · calibrated p 8e-5 ✓ | 33.2 EB05 31.4 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious PRR 28.4 · ♀ 100% (drug 63%) · 95% clinician | not reported in cached trials |
| Peripheral venous disease | 402 | 34.9 31.5–38.7ROR 35.1 · calibrated p 1e-4 ✓ | 31.4 EB05 28.9 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=400 · ♀ 100% (drug 63%) · 92% clinician | not reported in cached trials |
| Hand deformity | 1,271 | 33.6 31.7–35.5ROR 34.2 · calibrated p 1e-4 ✓ | 30.3 EB05 29.0 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 26.1 · ♀ 100% (drug 63%) · 96% clinician | not reported in cached trials |
| Autoimmune disorder | 890 | 32.0 29.8–34.2ROR 32.4 · calibrated p 2e-4 ✓ | 29.0 EB05 27.5 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious PRR 24.5 · ♀ 98% (drug 63%) · 93% clinician | not reported in cached trials |
| Subcutaneous drug absorption impaired | 50 | 31.5 23.5–42.1ROR 31.5 · calibrated p 3e-4 ✓ | 28.4 EB05 22.4 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=48 · ♀ 100% (drug 63%) · 100% clinician | not reported in cached trials |
| Lip dry | 793 | 30.3 28.2–32.6ROR 30.6 · calibrated p 2e-4 ✓ | 27.6 EB05 26.1 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=771 · ♀ 100% (drug 63%) · 94% clinician | not reported in cached trials |
| Hyperparathyroidism secondary | 224 | 30.3 26.4–34.7ROR 30.4 · calibrated p 3e-4 ✓ | 27.6 EB05 24.7 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=224 | not reported in cached trials |
| Nephrogenic anaemia | 403 | 29.4 26.6–32.6ROR 29.6 · calibrated p 3e-4 ✓ | 26.9 EB05 24.8 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=403 | not reported in cached trials |
| Drug tolerance decreased | 241 | 29.4 25.7–33.5ROR 29.5 · calibrated p 3e-4 ✓ | 26.8 EB05 24.1 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=238 · ♀ 100% (drug 63%) · 90% clinician | not reported in cached trials |
| Rebound acid hypersecretion | 263 | 29.2 25.8–33.2ROR 29.4 · calibrated p 3e-4 ✓ | 26.7 EB05 24.1 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=263 · 100% consumer | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Interstitial lung disease | 1,027 | 3.43.2–3.6 | signal |
| Liver injury | 2,999 | 3.13.0–3.2 | signal |
| Severe cutaneous reaction | 736 | 3.12.9–3.3 | signal |
| Pancreatitis | 783 | 3.12.8–3.3 | signal |
| Kidney injury | 4,030 | 2.82.7–2.9 | signal |
| Serious infection | 6,146 | 2.52.4–2.6 | signal |
| Tendon disorder | 300 | 2.52.2–2.8 | signal |
| Depression | 2,029 | 2.32.2–2.4 | signal |
| Arrhythmia / qt | 1,148 | 1.91.8–2.0 | raised |
| Anaemia | 1,709 | 1.81.7–1.9 | raised |
| Hyperglycaemia / diabetes | 1,937 | 1.81.7–1.8 | raised |
| Thrombocytopenia | 1,180 | 1.71.6–1.8 | raised |
| Gi bleeding | 934 | 1.61.5–1.7 | raised |
| Venous thromboembolism | 1,086 | 1.61.5–1.7 | raised |
| Hyponatraemia | 385 | 1.51.4–1.7 | raised |
| Opportunistic infection | 605 | 1.41.3–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Doxycycline Hyclate as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT01320033 — Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Ca (N=662, PHASE2; 15 AE terms posted; arms: CD2475/101 40 mg; Doxycycline 100 mg; Placebo)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 5,259 | 1.2 1.2–1.3ROR 1.3 · calibrated p 0.488 | 1.2 EB05 1.2 · IC025 +0.3 | Reporting / coding artifact | age-adj. PRR 1.5 · serious PRR 2.1 | not reported in cached trials |
| Nausea | 5,003 | 2.0 1.9–2.0ROR 2.1 · calibrated p 0.980 | 2.0 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.3 | NCT01320033: 14/223 (6.3%) on Doxycycline Hyclate; 4/222 (1.8%) control |
| Off label use (used outside approved label) | 4,777 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.818 | 1.7 EB05 1.7 · IC025 +0.7 | Reporting / coding artifact | age-adj. PRR 1.7 · serious PRR 2.0 | not reported in cached trials |
| Fatigue (tiredness) | 4,681 | 1.9 1.8–1.9ROR 2.0 · calibrated p 0.919 | 1.9 EB05 1.8 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 2.2 | not reported in cached trials |
| Rash | 4,160 | 3.0 2.9–3.1ROR 3.2 · calibrated p 0.579 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.0 · serious PRR 4.0 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 4,041 | 2.2 2.2–2.3ROR 2.3 · calibrated p 0.893 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.0 · serious PRR 2.2 | not reported in cached trials |
| Diarrhoea (diarrhea) | 4,035 | 2.0 1.9–2.0ROR 2.0 · calibrated p 0.959 | 2.0 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 2.1 | not reported in cached trials |
| Pain | 3,982 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.994 | 2.0 EB05 2.0 · IC025 +1.0 | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.1 | not reported in cached trials |
| Headache | 3,905 | 2.0 1.9–2.0ROR 2.0 · calibrated p 0.952 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.5 | NCT01320033: 15/223 (6.7%) on Doxycycline Hyclate; 6/222 (2.7%) control |
| Vomiting | 3,848 | 2.6 2.5–2.7ROR 2.7 · calibrated p 0.742 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 2.6 · ♀ 83% (drug 63%) | NCT01320033: 15/223 (6.7%) on Doxycycline Hyclate; 5/222 (2.3%) control |
| Drug hypersensitivity | 3,740 | 6.1 5.9–6.3ROR 6.4 · calibrated p 0.125 | 6.0 EB05 5.9 · IC025 +2.5 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 5.8 · serious PRR 6.3 · ♀ 87% (drug 63%) | not reported in cached trials |
| Malaise (feeling unwell) | 2,988 | 2.1 2.1–2.2ROR 2.2 · calibrated p 0.959 | 2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.5 | not reported in cached trials |
| Condition aggravated | 2,942 | 3.1 3.0–3.2ROR 3.2 · calibrated p 0.577 | 3.0 EB05 3.0 · IC025 +1.5 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 2.7 · serious PRR 3.2 | not reported in cached trials |
| Dizziness | 2,916 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.873 | 1.8 EB05 1.8 · IC025 +0.8 | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 2.1 | not reported in cached trials |
| Pruritus (itching) | 2,904 | 2.4 2.3–2.5ROR 2.5 · calibrated p 0.823 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.2 · serious PRR 3.5 | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Amyloid arthropathy — n=55, PRR 1,878.3
- Grip strength — n=142, PRR 501.7
- Congenital hiatus hernia — n=119, PRR 365.8
- Deep vein thrombosis postoperative — n=869, PRR 250.3
- Swollen joint count — n=106, PRR 237.8
- Lupus vulgaris — n=509, PRR 234.9
- Gastrointestinal mucosal necrosis — n=56, PRR 200.1
- Abortion incomplete — n=553, PRR 129.7
- Adjustment disorder with depressed mood — n=510, PRR 105.9
- Rheumatic fever — n=1,095, PRR 104.6
✓ A hand-written Bradford Hill causality assessment exists for this drug: Doxycycline (tetracyclines) ↔ Photosensitivity reaction.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Doxycycline Hyclate?
In FDA FAERS, the most frequently co-reported reaction terms for Doxycycline Hyclate are nausea, fatigue, rash, dyspnoea, diarrhoea, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Doxycycline Hyclate have an FDA boxed warning?
No. The FDA label retrieved for Doxycycline Hyclate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Doxycycline Hyclate causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 051654c7-8ba6-44f2-842c-72f515e9b32d, effective 20260915; matched on
openfda.generic_name.exact:"DOXYCYCLINE HYCLATE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,205 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
DOXYCYCLINE HYCLATE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.